Size Matters: Determination of critical control parameters for assay performance

每年开出的抗生素处方超过2.5亿张，其中近一半是盲目开的。不正确的处方会导致耐药性感染，每年导致120万人死亡，到2050年死亡人数将超过癌症。FluoretiQ的使命是为临床医生提供快速测试，以制作他们的第一个抗生素处方，正确的处方。我们的快速检测平台(Nanopex和SCFI)将诊断和抗生素选择的周转时间从几天减少到几分钟，从而制造出第一个处方，正确的处方。Nanopex是一种先进的乳胶凝集试验，它使用葡聚糖探针和机器学习在15分钟内识别和量化细菌，而不是2天，准确率超过90%。我们的第一个产品是(代号)P5；这是一种来自Nanopex系列的15分钟诊断测试。P5解决了对尿路感染(UTI)的准确护理点检测的未得到满足的需求，全球每年有1.5亿人受到影响。P5将提供明确的治疗/不治疗来自第一次会诊的证据。P5确定了最重要的尿路病原体。在这个项目中，FluoretiQ将与国家物理实验室(NPL)和牛顿数学门户(Newton)的专家合作，创建Nanopex分析的数学模型，该模型将有助于确定其他控制参数，以保持测试的性能。

Over 250 million antibiotic prescriptions are issued annually; nearly half are done blindly. Incorrect prescriptions lead to drug resistant infections, which kill 1.2 million people annually and will kill more people than cancer by 2050\. FluoretiQ's mission is to provide clinicians with rapid tests to make their first antibiotic prescription, the right prescription. Our rapid testing platforms (NANOPLEX & SCFI) reduce diagnosis and antibiotic selection turnaround time from days to minutes, making the first prescription, the right prescription. NANOPLEX is an advanced latex agglutination test that uses glycan probes and machine learning to identify and quantify bacteria in 15 mins rather than 2 days, with over 90% accuracy. The first of our products is (codenamed) P5; a 15-minute diagnostic test from the NANOPLEX family. P5 addresses the unmet need for accurate point of care testing of urinary tract infections (UTIs) that affects 150 million people globally each year. P5 will provide a clear treat/do not treat evidence from the first consultation. P5 identifies the most important uropathogens.For this project, FluoretiQ will collaborate with experts from the National Physics Laboratory (NPL) and Newton Gateway to Mathematics (Newton) to create a mathematical model of the NANOPLEX assay which will help identify additional control parameters for maintaining performance of the test.